- Home
- / Valneva
Valneva
Stock Price
€2.8
2024-10-29
Market Capitalization
€446.9 M
2024-10-29
Revenue
€157.9 M
FY, 2025
Valneva Summary
Company Summary
- Overview
- Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. It develops vaccines against Lyme disease, COVID-19, and chikungunya. Valneva also offers two commercial vaccines for travelers.
- Type
- Public
- Status
- Active
- Founded
- 2013
- HQ
- Saint-Herblain, FR | view all locations
- Website
- http://www.valneva.com
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Franck Grimaud, President & Chief Business Officer
Frederic Jacotot, General Counsel and Corporate Secretary
Juan Carlos Jaramillo, Chief Medical Officer
LocationsView all
8 locations detected
Saint-Herblain, Pays de la Loire HQ
France
6 Rue Alain Bombard
Gaithersburg, MD
United States
910 Clopper Rd #160S
Wien, Wien
Austria
Campus-Vienna-Biocenter 3
Kirkland, QC
Canada
3535 Boulevard Saint-Charles #600
Lyon, Auvergne-Rhône-Alpes
France
12 Quai Perrache batiment a
Solna, Stockholms län
Sweden
Gunnar Asplunds allé 16
Valneva Financials
Summary Financials
- Revenue (FY, 2025)
- €157.9M
- Gross profit (FY, 2025)
- €177.7M
- Net income (FY, 2025)
- (€115.2M)
- Cash (FY, 2025)
- €109.7M
- EBIT (FY, 2025)
- (€81.6M)
- Enterprise value
- $544.5M